Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 12:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 7,996 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Ischemic Stroke (AIS)
Interventions
Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels)
Drug
Lead sponsor
Silver Creek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more
Conditions
Selected Advanced Solid Tumors
Interventions
EOS006215, Anticancer agent
Drug
Lead sponsor
iTeos Belgium SA
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Denver, Colorado • Sarasota, Florida
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Interventions
CDX-585
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction (DDI) Rifabutin

NCT02138084
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Rifabutin, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Conditions
Renal Transplant Recipients With Anti-HLA Antibodies
Interventions
Not listed
Lead sponsor
Databean
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more
Conditions
Sleep Initiation and Maintenance Disorders, Pregnancy
Interventions
No Intervention
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
16 Years to 49 Years · Female only
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Nutley, New Jersey
Conditions
Gastric Cancer, Gastric Neoplasm, Gastrointestinal Stromal Sarcoma, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor (GIST)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neoplasms, Carcinoma, Non Small Cell Lung, Breast Neoplasms, Ovarian Neoplasms
Interventions
PF-06263507
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Philadelphia, Pennsylvania
Conditions
Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Interventions
RO7566802, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more
Conditions
Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms, Prostatic Cancer
Interventions
androgen ablation (AA), DC1 vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast
Interventions
BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort
Biological
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Franz Rischard, DO
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Interventions
ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
12
States / cities
Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more
Completed No phase listed Observational Accepts healthy volunteers

Expression of IFN-epsilon in the Female Reproductive Tract

NCT02416154
Conditions
Interferon Expression in the Female Reproductive Tract
Interventions
Reproductive tract and blood sampling
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
6
States / cities
Long Beach, California • Bay Harbor Islands, Florida • DeLand, Florida + 3 more
Conditions
Advanced Cancer, Metastatic Cancer
Interventions
Mocaciclib (Q901), KEYTRUDA® (pembrolizumab), Fulvestrant
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Conditions
Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
Interventions
Nivolumab, Trametinib, Ipilimumab, Regorafenib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Conditions
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
Biological
Lead sponsor
Simcha IL-18, Inc.
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more
Conditions
Epileptic Encephalopathy, SCN2A Encephalopathy
Interventions
1mg elsunersen, 0.5mg elsunersen
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
1 Day to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more
Conditions
Diffuse Large B-cell Lymphoma
Interventions
GCS-100, Etoposide; Dexamethasone
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
Interventions
Cerdulatinib, Rituximab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
23
States / cities
Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
Conditions
Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
Interventions
CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Solid Tumor
Interventions
SKB264, Pembrolizumab
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Anderson, Indiana • Louisville, Kentucky • Annapolis, Maryland + 5 more